Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-17T14:40:59.719Z Has data issue: false hasContentIssue false

Chapter 23 - Functional imaging markers as outcome measures in clinical trials for Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Ryan R. Walsh
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 242 - 248
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ravina, B, Eidelberg, D, Ahlskog, JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208–15.CrossRefGoogle ScholarPubMed
Bernheimer, H, Birkmayer, W, Hornykiewicz, O, Jellinger, K, Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415–55.CrossRefGoogle ScholarPubMed
Stoessl, AJ, Martin, WW, McKeown, MJ, Sossi, V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011; 10: 987–1001.CrossRefGoogle ScholarPubMed
Brooks, DJ, Pavese, N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011; 95: 614–28.CrossRefGoogle ScholarPubMed
Brooks, DJ. The role of structural and functional imaging in parkinsonian states with a description of PET technology. Semin Neurol 2008; 28: 435–45.CrossRefGoogle ScholarPubMed
Vingerhoets, FJ, Schulzer, M, Calne, DB, Snow, BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol, 1997; 41: 58–64.CrossRefGoogle ScholarPubMed
de la Fuente-Fernandez, R, Schulzer, M, Mak, E, Sossi, V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord 2010; 16: 365–9.Google Scholar
Scherfler, C, Schwarz, J, Antonini, A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22: 1229–38.CrossRefGoogle ScholarPubMed
Laruelle, M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423–51.CrossRefGoogle ScholarPubMed
Pavese, N, Evans, AH, Tai, YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612–17.CrossRefGoogle ScholarPubMed
Baglieri, A, Marino, MA, Morabito, R, et al. Differences between conventional and nonconventional MRI techniques in Parkinson's disease. Funct Neurol 2013; 28: 73–82.Google Scholar
Cho, ZH, Oh, SH, Kim, JM, et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov Disord 2011; 26: 713–18.CrossRefGoogle ScholarPubMed
Mahlknecht, P, Hotter, A, Hussl, A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010; 7: 300–18.CrossRefGoogle ScholarPubMed
Peran, P, Cherubini, A, Assogna, F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133: 3423–33.CrossRefGoogle ScholarPubMed
Tang, CC, Eidelberg, D. Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside. Prog Brain Res 2010; 184: 161–76.Google Scholar
Niethammer, M, Feigin, A, Eidelberg, D. Functional neuroimaging in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: a009274.CrossRefGoogle ScholarPubMed
Stoessl, AJ. Neuroimaging in Parkinson's disease. Neurotherapeutics 2011; 8: 72–81.Google Scholar
Nandhagopal, R, McKeown, MJ, Stoessl, AJ. Functional imaging in Parkinson disease. Neurology 2008; 70: 1478–88.CrossRefGoogle ScholarPubMed
Berg, D. Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm 2011; 118: 453–61.CrossRefGoogle ScholarPubMed
Ouchi, Y, Yagi, S, Yokokura, M, Sakamoto, M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 3): S200–4.CrossRefGoogle ScholarPubMed
Yarnall, A, Rochester, L, Burn, DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011; 26: 2496–503.CrossRefGoogle ScholarPubMed
Vernon, AC, Ballard, C, Modo, M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Brain Res Rev 2010; 65: 28–55.CrossRefGoogle ScholarPubMed
Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629–35.Google Scholar
Catana, C, Drzezga, A, Heiss, WD, Rosen, BR. PET/MRI for neurologic applications. J Nucl Med 2012; 53: 1916–25.Google Scholar
Stern, MB, Lang, A, Poewe, W. Toward a redefinition of Parkinson's disease. Mov Disord 2012; 27: 54–60.CrossRefGoogle Scholar
Brooks, DJ, Frey, KA, Marek, KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184 (Suppl. 1): S68–79.CrossRefGoogle ScholarPubMed
Agarwal, PA, Stoessl, AJ. Biomarkers for trials of neuroprotection in Parkinson's disease. Mov Disord 2013; 28: 71–85.CrossRefGoogle ScholarPubMed
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–61.CrossRefGoogle Scholar
Whone, AL, Watts, RL, Stoessl, AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101.CrossRefGoogle ScholarPubMed
Fahn, S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 (Suppl. 4): IV37–42.Google Scholar
Jack, CR Jr, Holtzman, DM. Biomarker modeling of Alzheimer's disease. Neuron 2013; 80: 1347–58.CrossRefGoogle ScholarPubMed
Lim, SY, Fox, SH, Lang, AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66: 167–72.CrossRefGoogle ScholarPubMed
Doherty, KM, Silveira-Moriyama, L, Parkkinen, L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013; 70: 571–9.Google Scholar
Alves, G, Wentzel-Larsen, T, Aarsland, D, Larsen, JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005; 65: 1436–41.CrossRefGoogle ScholarPubMed
Benedetti, F, Carlino, E, Pollo, A. How placebos change the patient's brain. Neuropsychopharmacology 2011; 36: 339–54.Google Scholar
Lidstone, SC, Schulzer, M, Dinelle, K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857–65.Google Scholar
Weiner, MW, Veitch, DP, Aisen, PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012; 8 (Suppl.): S1–68.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×